Li CY. Progress of the study on blood stasis syndrome and prescriptions and medicinal herbs activating blood circulation to eliminate stasis. Chin J Integr Tradit West Med (Chin) 1988;8:317–320.

Dai RH, Luo XP. Retrospect and prospect on prevention and treatment of coronary heart disease with integrative Chinese and Western medicine. Chin J Integr Tradit West Med (Chin) 2006;26:101.

Shang H, Zhang J, Yao C, Liu B, Gao X, Ren M, et al. Qishen Yiqi Dripping Pills for the secondary prevention of myocardial infarction: a randomized clinical trial. Evid Based Complement Alternat Med 2013;2013:738391.

Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. Circulation 2011;124:2574–2609.

Lu XY, Shi DZ, Xu H, Chen KJ, Lu SZ. Clinical study on effect of Xiongshao Capsule on restenosis after percutaneous coronary intervention. Chin J Integr Tradit West Med (Chin) 2006;26:13–17.

Chen BJ, Pan ZQ, Su XX. Study on changes of Chinese medicine syndrome in patients with coronary heart disease before and after intervention treatment. Chin J Integr Tradit West Med (Chin) 2007;27:689–691.

Wang SL, Wang CL, Wang PL, Xu H, Liu HY, Du JP, et al. Combination of Chinese herbal medicines and conventional treatment versus conventional treatment alone in patients with acute coronary syndrome after percutaneous coronary intervention (5C Trial): An open-label randomized controlled, multicenter study. Evid Based Complement Alternat Med 2013;2013:741518.

Pagley PR, Beller GA, Watson DD, Gimple LW, Ragosta M. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation 1997;96:793–800.

Li X, Zhang J, Huang J, Ma A, Yang J, Li W, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of Qili Qiangxin Capsules in patients with chronic heart failure. J Am Coll Cardiol 2013;62:1065–1072.

Wang S, Li P, Ran D, Wang X, Xue J, Chen Z. A randomized, double-blind, placebo control and multicenter clinical trial for Tiankui antihypertension tablets combined with chemical drugs in the treatment of hypertension. China Pharmacist (Chin) 2015;18:964–967.

Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008;101:1689–1693.

Ji L, Tong X, Wang H, Tian H, Zhou H, Zhang L, et al. Efficacy and safety of traditional Chinese medicine for diabetes: a double-blind, randomised, controlled trial. PLoS One 2013;8:e56703.